
Show Notes
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the August 2022 issue of DTB. They discuss progress in reducing use of psychotropic medications in adults and children with a learning disability, autism or both (https://dtb.bmj.com/content/60/8/114). They also provide an overview of a study that assessed the effect of deprescribing antihypertensive medication in older people (https://dtb.bmj.com/content/60/8/118) and talk about a national safety alert relating to amiodarone (https://dtb.bmj.com/content/60/8/116). They end the podcast with a discussion on the evidence for the lipid-lowering drug bempedoic acid and its effect on reducing low-density lipoprotein-cholesterol and the lack of evidence on clinical outcomes (https://dtb.bmj.com/content/60/8/120). The contact address for the DTB team is [email protected]. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
More from DTB Podcast
The perspective on medical care changes when the doctor becomes a patient. In the October episode, host Dr Hannah Harris (DTB's Clinical Editor and GP) speaks with the newly appointed Editor-in-Chief, Dr Gordon Mallarkey, to introduce themselves to the DTB podcast listeners and discuss the latest edition of the journal. Hannah summarises her editorial about doctor-patient communication, reflecting on medical gaslighting and her personal experience as a breast cancer patient.They also discuss a drug review on Inbrija, an inhaled powder form of levodopa, used to treat intermittent 'OFF' motor episodes in Parkinson’s disease, and conclude with a review of spasticity management, covering non-pharmacological, oral, injectable, and surgical options. Read the issue on our website: https://dtb.bmj.com/content/64/10.
The DTB podcast returns with a new format, and a new host: Dr Hannah Harris, urgent care GP and Clinical Editor of DTB.
In this podcast accompanying the March 2026 issue of the DTB (https://dtb.bmj.com/content/64/3), Syba Sunny (DTB Clinical Editor) is joined by Shivali Fulchand (Editorials and Education editor at The BMJ). Syba and Shivali discuss this month’s editorial on clinically important differences (https://dtb.bmj.com/content/64/3/34) and talk about why this is such an important topic. Then they go on to talk through the DTB’s drug review on the new adrenaline nasal spray that’s been formulated for the treatment of anaphylaxis (https://dtb.bmj.com/content/64/3/36).
In this podcast accompanying the February 2026 issue of the DTB (https://dtb.bmj.com/content/64/2), Syba Sunny (DTB Clinical Editor) is joined by Julian Treadwell (DTB Associate Editor). Syba and Julian start by talking about this month’s ‘thank you’ editorial (https://dtb.bmj.com/content/64/2/18) before delving into the hot topic of GLP-1 drugs for the treatment of obesity, which is the subject of a DTB review article that summarises what is known about their benefits and harms (https://dtb.bmj.com/content/64/2/19). Finally, they discuss an intervention to reduce sedative use in patients who have been taking these drugs for a long time (https://dtb.bmj.com/content/64/2/25).
In this podcast accompanying the January 2026 issue of the DTB (https://dtb.bmj.com/content/64/1), Syba Sunny (DTB Clinical Editor) is joined by Tom Nolan, an NHS general practitioner and Clinical Editor at BMJ Medicine. Syba and Tom first talk through this month’s editorial on disinformation and misinformation (https://dtb.bmj.com/content/64/1/2), and discuss ways to combat these in medicine. They then provide an overview of a DTB Forum article, which explains the benefits of taking people off antidepressants using the hyperbolic tapering method (https://dtb.bmj.com/content/64/1/3). The episode ends with Tom sharing his thoughts about the role of artificial intelligence (AI) in primary care.